Intrapleural or Intraperitoneal Lobaplatin for Treatment of Patients with Malignant Pleural Effusion or Ascites

Aims: To explore efficacy and side effects of intrapleural or intraperitoneal lobaplatin for treating patients with malignant pleural or peritoneal effusions. Methods: Patients in Jiangsu Cancer Hospital and Research Institute with cytologically confirmed solid tumors complicated with malignant pleural effusion or ascites were enrolled into this study. Lobaplatin (20-30 mg/m 2 ) was intrapleurally or intraperitoneally infused for patients with malignant pleural effusion or ascites. Results: From 2012 to 2013, intrapleural or intraperitonea lobaplatin was administered for patients with colorectal or uterus cancer who were previous treated for malignant pleural effusion or ascites. Partial response was achieved for them. Main side effects were nausea/vomiting, and bone marrow suppression. No treatment related deaths occurred. Conclusion: Intrapleural or intraperitoneal infusion of lobaplatin is a safe treatment for patients with malignant pleural effusion or ascites, and the treatment efficacy is encouraging. most commonly associated to ascites are ovarian (37%), pancreatic biliary (21%), gastric (18%), oesophageal (4%), colorectal (4%), and breast (3%) (Ayantunde, 2007). Intracavitary administration of anticancer drugs is a common method for treating malignant pleural effusion or ascites. Platinums are the common used drugs, cisplatin and carboplatin have been reported (Bogholo et al., 1991; Esposito et al., 1994). We hypothesize that intrapleural lobaplatin is also an effective option for patients with malignant pleural effusion or ascites.